NCT01703754View on ClinicalTrials.gov

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 4, 2013

Primary Completion Date

August 7, 2014

Study Completion Date

August 7, 2014

Conditions
Breast Cancer Nos Metastatic Recurrent
Interventions
GENETIC

Ad-RTS-hIL-12 and Veledimex

Oral activator ligand with adenoviral vector injection of cancer lesions

DRUG

Palifosfamide

Small molecule chemotherapy, IV administration

Trial Locations (8)

29605

Greenville Hospital System, Greenville

32207

Baptist Cancer Institute, Jacksonville

38138

The Jones Clinic, PC, Germantown

45042

Signal Point Clinical Research Center, Middletown

48202

Henry Ford Health System, Detroit

59101

Billings Clinic, Billings

75201

Mary Crowley Medical Research Center, Dallas

99218

Evergreen Hematology & Oncology, Spokane

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY